## Evaluation of acylated ghrelin and obestatin levels and ghrelin/obestatin ratio in obesity

## Maryam Razzaghy Azar<sup>1,3</sup>Mitra Nourbakhsh<sup>2,3</sup>, Abdolreza Pourmoteabed<sup>1</sup>, Mona Nourbakhsh<sup>1</sup>, Davod Ilbeigi <sup>3</sup>, Zahra Arab<sup>3</sup>

<sup>1,</sup> H. Aliasghar Hospital, Iran University of Medical Sciences (IUMS); <sup>2,</sup> Department of Biochemistry, School of Medicine, IUMS. <sup>3.</sup> Metabolic Disorders Research Center, Molecular-Cellular Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran

Background: Ghrelin is 28-amino acid peptide predominantly produced by the stomach and have an orexigenic property as well as potent GH-releasing activity. Acylated ghrelin (AG) is the active form of this hormone. Obestatin is a 23-amino acid peptide, is produced by post-translational modification of a protein precursor that also produces ghrelin. Obestatin has the opposite effect of ghrelin on food intake

Objective and hypotheses: To evaluate acylated ghrelin and obestatin levels in obese and normal weight children and adolescents and their association with metabolic syndrome (MetS) and its parameters.

Method: Children and adolescents, 73 (31 normal weight control; 42 obese), aged 7-16 years, Serum AG, obestatin, insulin (ELISA), fasting plasma glucose (FPG), triglyceride (TG), total cholesterol (TC), low and high density lipoprotein (LDL-C and HDL-C) were measured. Insulin resistance was calculated by Homeostasis Model Assessment of Insulin Resistance (HOMA-IR). Metabolic syndrome was determined according to IDF criteria. Data for AG and obestatin were presented as median (25-75 percentiles).









